Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.
Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026
See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.
FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.
Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?
Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.
Why Bambusa Therapeutics’ BBT001 data are drawing attention in atopic dermatitis beyond a routine Phase 1 update
Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.
What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
MindWalk adds VHH capability as nanobodies gain ground in CAR-T and multispecific design
MindWalk launches B Cell Llama, a VHH nanobody platform for bispecific drug design. Peer-reviewed data raises key questions about function, immunogenicity, and AI.
J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results
FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.
Johnson & Johnson’s TECVAYLI may redefine second-line myeloma care after MajesTEC-9
TECVAYLI outperformed standard regimens in relapsed/refractory myeloma. Find out what the Phase 3 MajesTEC-9 trial means for future treatment lines.